Roivant Sciences Reports Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy ROIV?
Source: stocktwits
- Clinical Trial Results: Roivant Sciences reported in the BEACON trial that patients receiving the 45 mg dose of brepocitinib experienced significant reductions in skin disease activity, showing statistically meaningful benefits as early as four weeks and maintaining improvements through week 16, indicating the drug's potential in treating cutaneous sarcoidosis.
- Earnings Report: The company announced Q3 revenue of $1.9 million, falling short of analysts' expectations of $6.14 million, although an EPS loss of $0.38 exceeded consensus, highlighting challenges in revenue growth while showing improvements in profitability.
- Market Reaction: Following the earnings release, Roivant's stock rose over 9% in pre-market trading on Friday, reflecting investor optimism regarding the clinical trial results, which may drive future funding and R&D advancements for the company.
- Future Outlook: With positive results for brepocitinib in treating cutaneous sarcoidosis, Roivant is likely to attract increased investor interest and may accelerate subsequent clinical trials and market launch plans to meet the growing patient demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROIV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROIV
Wall Street analysts forecast ROIV stock price to fall
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.850
Low
22.00
Averages
27.63
High
33.00
Current: 27.850
Low
22.00
Averages
27.63
High
33.00
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Settles for $2.25 Billion with Genevant and Arbutus Over Patent Infringement
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent on a favorable appeal ruling, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting Moderna's accountability in patent infringement cases.
- Patent Licensing Agreement: Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation against Moderna and ensuring compliance for future technology use.
- Significant Market Impact: This settlement not only resolves a long-standing dispute for Moderna but may also affect its competitive position in the COVID-19 vaccine market, especially in light of ongoing litigation with Pfizer/BioNTech.
- Capital Return Plan: Arbutus announces it is evaluating a potential return of capital to shareholders in Q3 2026, which, combined with the upfront payment from the settlement, could enhance investor confidence and improve the company's financial standing.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
Moderna Settles $2.25 Billion Patent Dispute with Genevant and Arbutus
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a successful appeal, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting the importance of intellectual property.
- Technology Licensing Agreement: As part of the settlement, Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation related to its COVID-19 vaccines, ensuring the legality of Moderna's products.
- Acknowledgment of Legal Liability: Moderna agrees to acknowledge infringement on four Genevant/Arbutus patents and consents to a court judgment of no invalidity, which not only reduces future legal risks but also secures the company's ongoing operations in the vaccine market.
- Positive Market Reaction: This settlement is expected to provide significant cash inflow for Roivant, enhancing its capital efficiency and supporting a $500 million share repurchase plan, which will further boost investor confidence and potentially drive stock price appreciation.
See More
Priovant Secures FDA Priority Review for Brepocitinib
- FDA Priority Review: Priovant Therapeutics announced that its drug brepocitinib for dermatomyositis has received priority review from the FDA, marking a significant advancement in the treatment of rare diseases and potentially accelerating the drug's market entry.
- Clinical Trial Results: The New Drug Application is supported by data from the Phase 3 VALOR study involving 241 patients, where brepocitinib at a 30 mg dose demonstrated statistically significant improvement in the myositis Total Improvement Score, achieving the study's primary endpoint and enhancing the likelihood of FDA approval.
- Market Potential: If approved, brepocitinib will be the first FDA-approved targeted therapy for dermatomyositis, expected to fill a market gap and meet the urgent need for effective treatments, thereby enhancing Priovant's market position.
- Company Commitment: Priovant CEO Ben Zimmer stated that the company is committed to working closely with the FDA to expedite the drug's availability, reflecting its strong focus on patient welfare and proactive engagement with market opportunities.
See More
Moderna Settles for $2.25 Billion with Genevant and Arbutus Over Patent Infringement
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent on a favorable appeal ruling, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting Moderna's accountability in patent infringement cases.
- Patent Licensing Agreement: Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation against Moderna and ensuring compliance for future technology use.
- Significant Market Impact: This settlement not only resolves a long-standing dispute for Moderna but may also affect its competitive position in the COVID-19 vaccine market, especially in light of ongoing litigation with Pfizer/BioNTech.
- Capital Return Plan: Arbutus announces it is evaluating a potential return of capital to shareholders in Q3 2026, which, combined with the upfront payment from the settlement, could enhance investor confidence and improve the company's financial standing.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
Moderna Settles $2.25 Billion Patent Dispute with Genevant and Arbutus
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a successful appeal, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting the importance of intellectual property.
- Technology Licensing Agreement: As part of the settlement, Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation related to its COVID-19 vaccines, ensuring the legality of Moderna's products.
- Acknowledgment of Legal Liability: Moderna agrees to acknowledge infringement on four Genevant/Arbutus patents and consents to a court judgment of no invalidity, which not only reduces future legal risks but also secures the company's ongoing operations in the vaccine market.
- Positive Market Reaction: This settlement is expected to provide significant cash inflow for Roivant, enhancing its capital efficiency and supporting a $500 million share repurchase plan, which will further boost investor confidence and potentially drive stock price appreciation.
See More
Priovant Secures FDA Priority Review for Brepocitinib
- FDA Priority Review: Priovant Therapeutics announced that its drug brepocitinib for dermatomyositis has received priority review from the FDA, marking a significant advancement in the treatment of rare diseases and potentially accelerating the drug's market entry.
- Clinical Trial Results: The New Drug Application is supported by data from the Phase 3 VALOR study involving 241 patients, where brepocitinib at a 30 mg dose demonstrated statistically significant improvement in the myositis Total Improvement Score, achieving the study's primary endpoint and enhancing the likelihood of FDA approval.
- Market Potential: If approved, brepocitinib will be the first FDA-approved targeted therapy for dermatomyositis, expected to fill a market gap and meet the urgent need for effective treatments, thereby enhancing Priovant's market position.
- Company Commitment: Priovant CEO Ben Zimmer stated that the company is committed to working closely with the FDA to expedite the drug's availability, reflecting its strong focus on patient welfare and proactive engagement with market opportunities.
See More
